Acurastem Incorporated
Pasadena, CA Doing business as Acurastem Inc.
- UEI
- EHEBD1K16MJ4
- CAGE
- 7KRR1
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 150 N Orange Grove Blvd #220, Pasadena, CA 91103, USA
- Website
- acurastem.com
- Founded
- 2016
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Health Care Equipment & Services
- Health Care Providers & Services
- SIC code
- 38 Instruments & Related Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Late-stage development of a pikfyve antisense oligonucleotide treatment for FTD | Defense Health Agency | $4,167,674 | |
| Development of an UNC13A antisense oligonucleotide treatment for ALS and FTD - development of an UNC13A antisense… | National Institute of Neurological Disorders and Stroke | $2,670,896 | |
| Development of a SYF2 antisense oligonucleotide treatment for ALS and FTD - development of a SYF2 antisense… | National Institute on Aging | $2,894,619 | |
| Development of an UNC13A antisense oligonucleotide treatment for ALS and FTD | Defense Health Agency | $839,898 | |
| Development of a pikfyve antisense oligonucleotide treatment for FTD - development of a pikfyve suppressing antisense… | National Institute of Neurological Disorders and Stroke | $7,293,686 |
About Acurastem Incorporated
Acurastem Inc., doing business as Acurastem, is a biotechnology company focused on developing treatments for neurodegenerative diseases like amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and additional indications. The company specializes in near to clinic, patient based therapeutics.
Through prime federal grant awards, Acurastem Inc. has received funding to support the development of novel antisense oligonucleotide treatments targeting genes implicated in ALS and FTD, such as UNC13A, SYF2, and PIKFYVE. Major funding has come from the National Institutes of Health National Institute on Aging, the National Institutes of Health National Institute of Neurological Disorders and Stroke, and the Defense Health Agency under programs focused on aging research, neurological disorders research, and military medical research and development. In total, Acurastem Inc. has been awarded over $15 million in federal grants from 2021-2023 to advance its ALS and FTD treatment pipeline. Additionally, Acurastem Inc. has received a federal subaward from Pennsylvania State University related to small molecule drug discovery for ALS.
Quick answers
What is Acurastem Incorporated's UEI?
Acurastem Incorporated's Unique Entity ID (UEI) in SAM.gov is EHEBD1K16MJ4.
What is Acurastem Incorporated's CAGE code?
Acurastem Incorporated's CAGE code is 7KRR1.
What is Acurastem Incorporated's primary NAICS code?
Acurastem Incorporated's primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Acurastem Incorporated located?
Acurastem Incorporated's physical address in SAM.gov is 150 N Orange Grove Blvd #220, Pasadena, CA 91103, USA.
Is Acurastem Incorporated registered in SAM.gov?
Yes. Acurastem Incorporated's SAM.gov registration is active through June 15, 2027.
What is Acurastem Incorporated's most recent federal award?
Acurastem Incorporated's most recent federal grant award is Late-stage development of a pikfyve antisense oligonucleotide treatment for FTD (HT94252311018), from Defense Health Agency, on September 15, 2023.
On GovTribe
See Acurastem Incorporated's full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors